Interleukin-6 Neutralization by Antibodies Immobilized at the Surface of Polymeric Nanoparticles as a Therapeutic Strategy for Arthritic Diseases

last updated: 2018-10-17
ProjectSPARTAN :: publications list
TitleInterleukin-6 Neutralization by Antibodies Immobilized at the Surface of Polymeric Nanoparticles as a Therapeutic Strategy for Arthritic Diseases
Publication TypePapers in Scientific Journals
Year of Publication2018
AuthorsLima, Ana C., Cunha C., Carvalho A., Ferreira H., and Neves N. M.
Abstract

Arthritic diseases are disabling conditions affecting millions of patients worldwide. Pro-inflammatory cytokines, particularly interleukin-6 (IL-6), plays a crucial role in inflammation and cartilage destruction. Although the beneficial effects of antibody therapy, its efficacy is limited. Therefore, this work proposes the immobilization of antibodies at the surface of biodegradable polymeric nanoparticles (NPs) to capture and neutralize IL-6. Our system is intended to protect, extend and enhance the therapeutic efficacy after delivery. Chitosan−hyaluronic acid NPs are synthesized as a stable monodisperse population. After determining the maximum immobilization capacity (10 μg/mL), the capture ability was confirmed. Biological assays demonstrate the NPs cytocompatibility with human articular chondrocytes (hACs) and human macrophages. hACs stimulated with macrophage conditioned medium shows the beneficial role of IL-6 capture and neutralization. Biofunctionalized NPs exhibit a prolonged action and stronger efficacy than the free antibody. In conclusion, this system can be an effective and long lasting treatment for arthritic diseases.

JournalAcs Applied Materials & Interfaces
Volume10
Issue16
Pagination13839-13850
Date Published2018-04-03
PublisherACS Publications
ISSN1944-8252
DOI10.1021/acsami.8b01432
URLhttp://dx.doi.org/10.1021/acsami.8b01432
Keywordsanti-IL-6 antibody immobilization, Arthritic diseases, biodegradable polymeric nanoparticles, IL-6 capture and neutralization, pro-inflammatory cytokine interleukin-6
RightsembargoedAccess (1 Year)
Peer reviewedyes
Statuspublished

Back to top